German biotech company BioNTech seems willing to establish itself as the market leader in the therapeutic field of vaccines. Indeed, the Mainz-based group announced that it has entered into a strategic research collaboration with the University of Pennsylvania (Penn), aimed at developing new mRNA-based vaccines for the treatment of infectious diseases. It is the second such agreement signed by BioNTech in the field of vaccines: in August, the company had already announced an agreement with Pfizer aimed at developing new mRNA-based influenza vaccines. As part of it, Pfizer is due to make an upfront payment over $120m, plus an additional $305m subject to fulfillment of precise milestones.
BioNTech was founded in Mainz in 2008 and now employs 850 people. Its main shareholder is Strüngmann Family Office. BioNTech has by now become the largest European biotech company still unlisted.